UNSPSC 51413401: Endralazine

This classification denotes a vasodilating agent with the molecular formula C14H15N5O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier L44741F05P, chemically known as 6-benzoyl-3-hydrazino-5,6,7,8-tetrahydropyrido(4,3-c)pyridazin but generally known as endralazine, which bears US NIH Compound Identifier 47608. European Medicines Agency schedules Endralazine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06525MIG.

UNSPSC 51413401 Endralazine is a Commodity code that encompasses medications used in emergency medical services and hospital-based acute care settings, as evidenced by recent state and local procurement activity focused on emergency cardiovascular and life-support pharmaceuticals. The code appears narrowly defined around a specific active pharmaceutical ingredient, yet the recent solicitations show state and local bodies purchasing advanced life support medications more broadly — including epinephrine, adenosine, diltiazem, and labetalol — often bundled together to meet urgent clinical demand. Issuing bodies range from city fire departments and emergency services (represented by the City of Tampa) to state health agencies and multi-state cooperative purchasing alliances (represented by Texas HHS and MMCAP). The Tampa Fire Rescue bid solicitation reflects direct municipal procurement of emergency medications, while the Minnesota and Texas opportunities show state-level and cooperative vehicles consolidating pharmacy procurement across multiple jurisdictions and healthcare delivery points.

Activity is concentrated in Texas and Minnesota, with secondary municipal procurement in Florida. The City of Tampa's Purchasing Department issued IFB 26P00188 for Advanced Life Support Medications with a due date of April 8, 2026 and an estimated contract value of $40,000, requiring 370 units of Labetalol HCI 100mg vials, 1,810 units of Epinephrine 1:10,000 injections, 330 units of Adenosine 6mg vials, and 1,020 units of Diltiazem 25mg vials with a one-year term and optional two additional one-year renewals plus discretionary 30-day extensions. The Minnesota Department of Administration's Office of State Procurement issued RFP S1070000015802 through the MMCAP cooperative purchasing vehicle for generic multi-source pharmaceuticals and OTC products with a March 26, 2026 due date and a two-year contract term effective July 1, 2026, requiring compliance with cGMP and DSCSA and distribution through AmerisourceBergen (Cencora), Cardinal Health, and Morris & Dickson. The Texas Health and Human Services Commission posted RFI HHS0017013 on March 27, 2026 with an April 3, 2026 response deadline to gather vendor capabilities for direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager and group purchasing organization channels. The City of Tampa's bid includes a 5 percent Small Local Business Enterprise sheltered market designation and requires Safety Data Sheets compliant with OSHA HCS.